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Recently, newer therapies have been designed to more specifically target rejection in an effort to improve efficacy and limit unwanted toxicity. Belatacept, a CD28-CD80/86 specific reagent, is associated with superior patient survival and graft function compared with traditional therapy, but its adoption as a mainstay immunosuppressive therapy has been tempered by increased rejection rates. It is essential that the underlying mechanisms associated with this rejection be elucidated before belatacept is more widely used. To that end, we designed a study in a nonhuman primate kidney transplant model where animals were treated with either a belatacept-or a tacrolimus-based immunosuppressive regimen. Interestingly, we found that elevated pretransplant frequencies of CD28 + CD8 + T EMRA cells are associated with rejection on belatacept but not tacrolimus treatment. Further analysis showed that the CD28 + CD8
+ T EMRA cells rapidly lose CD28 expression after transplant in those animals that go on to reject with the allograft infiltrate being predominantly CD28 À . These data suggest that CD28 + memory T cells may be resistant to belatacept, capable of further differentiation including loss of CD28 expression while maintaining effector function. The unique signaling requirements of CD28 + memory T cells provide opportunities for the development of targeted therapies, which may synergize with belatacept to prevent costimulation-independent rejection.
Introduction
Solid organ transplantation has become the primary treatment for end-stage organ failure. Success over the last 30 years has largely been driven by the advent of increasingly potent immunosuppressants. In particular, calcineurin inhibitors (CNIs) such as cyclosporine and tacrolimus were instrumental in reducing the incidence of early graft failure due to acute rejection. Despite these advances, long-term transplant outcomes have remained largely unchanged over the past 20 years (1) . Although this is likely multifactorial, the nonimmune side effects of CNIs, including nephrotoxicity, diabetes, hyperlipidemia, and increased overall cardiovascular risk, play an important role in diminishing long-term outcomes (2) (3) (4) . In 2011 the first non-CNI alternative, belatacept, was approved for use in kidney transplantation (5) . Belatacept is a high-affinity variant of the fusion protein CTLA4-Ig, which specifically blocks CD28-mediated T cell costimulation, providing a more targeted and less toxic form of immunosuppression than CNIs (6) . Kidney transplant patients treated with belatacept live longer and enjoy better renal function than those patients treated with cyclosporine (43% reduction in the risk of death or graft loss at 7-year follow-up) (7) (8) (9) (10) . Despite these improvements, use of belatacept has to date been tepid, mostly due to its association with more frequent and severe rejection episodes in a subset of patients (11) . Costimulation blockade-based strategies hold immense promise for improved long-term outcomes, but resistance to belatacept-based immunosuppression in a subset of patients demands further investigation into the underlying mechanisms of costimulation independence. Indeed, wider utilization of this more targeted, less toxic approach to transplant immunosuppression may hinge on the ability to phenotypically identify costimulation-independent cell subsets and understand their unique signaling requirements (12) . This knowledge will enhance both the clinical utility of belatacept as well as inform future strategies to optimize belatacept-based therapy.
Belatacept binds to CD80 and/or CD86, preventing the ligation of the CD28 costimulatory molecule expressed on the majority of T cells. The ability of cells to dispense with CD28 costimulation, potentially marked by CD28 loss, is one mechanism by which T cells may become belatacept resistant. Increases in CD28
À cells are associated with advanced age and chronic inflammation (13, 14) . More specifically, inflammatory cytokines such as tumor necrosis factor (TNF) (15), IL-2 (16), and IL-15 (17) drive the loss of CD28. Antigen exposure and the development of terminally differentiated T cell memory is also marked by the downregulation of CD28 (14, 18, 19) . Contextually, loss of CD28 or CD28 independence is part of a program of differentiation and cellular maturation marked by changes in receptor expression and cell functionality. Classic models of memory classification define CD4 and CD8 T cells by CCR7 and CD45RA or by CD28 and CD95 (20) (21) (22) . Multiparametric flow cytometry has revealed the phenotypic and functional heterogeneity of T cell subsets (23) (24) (25) (26) (27) . These studies reveal functional differences between subsets defined by four or more phenotypic markers at a time, with a potentially critical transition marked by CD28 loss (28) . Previous studies demonstrate that CD28 + cells retain enhanced antiviral capacity (22) and proliferative potential (29) , whereas loss of CD28 is associated with increased cytotoxicity, reduced responsiveness to T cell activation via the T cell receptor (29) , and the development of a dependence on homeostatic cytokine signaling for survival and effector function (30) (31) (32) . One study suggests that CD28
À

CD57
+ CD4 + T cells may be associated with increased risk of belatacept-resistant rejection (33) . How and when CD28 is lost following transplantation, and whether the loss of CD28 potentiates belatacept resistance, remain formally untested.
We investigated the mechanisms that underlie belatacept resistance in a preclinical nonhuman primate (NHP) model of kidney transplantation. Therapy was withdrawn day 140 posttransplantation, giving rise to two distinct study populations: belatacept-resistant animals that experienced early acute rejection during belatacept therapy, and belatacept-susceptible animals that demonstrated excellent graft function for the duration of belatacept treatment. Together with data from a separate clinical study of patients treated with belatacept (34), we observe that a critical threshold frequency of CD28 + , not CD28 À , memory T cells is associated with belatacept resistance. These CD28 + memory cells retain proliferative capacity and may eventually lose CD28 expression as they fully differentiate into cytotoxic effector T cells. These findings suggest that pretransplant immunophenotyping using the frequency of CD8 + CD28 + T EMRA T cells may provide a strategy to identify individuals who are susceptible to belatacept therapy, thereby reducing the risk of rejection.
Materials and Methods
Donor-recipient pair selection and kidney transplantation
All experiments described herein were performed in compliance with the principles set forth in The Guide for the Care and Use of Laboratory Animals (Institute of Laboratory Animal Resources, National Research Council, Department of Health and Human Services). Outbred rhesus monkeys (Macaca mulatta) ranging between 3 and 5 years old were obtained from AlphaGenesis, Inc. (Yemassee, SC) and Yerkes National Primate Research Center (Lawrenceville, GA). Donor-recipient pairs were chosen to maximize genetic disparity at both MHC class I and class II alleles based on 454 deep sequencing analysis (University of Wisconsin, Madison, WI). Kidney transplantation was performed using standard microvascular techniques (35) . Animals were heparinized (100 U/kg) during organ procurement and implantation. Left native nephrectomy was performed at least 3 weeks prior to transplantation, and a completion right native nephrectomy was performed at the time of transplantation. All transplanted animals were monitored with daily clinical assessment and serial laboratory evaluations, including complete blood count and serum chemistry.
NHP experimental groups and immunomodulation
All animals received methylprednisolone (subcutaneous injection according to the following schedule, day 0 (d0): 20 mg, d1: 16 mg, d2: 12 mg, d3: 8 mg, d4: 4 mg, d5-14: 3 mg, d15-140: 1 mg) and mycophenolate mofetil (30 mg/kg bid, d0-d140) to recapitulate clinically relevant immunosuppression strategy. A subset (n = 8/16) of belatacept-treated animals received basiliximab induction therapy (0.3 mg/kg d0, d4). All tacrolimustreated animals received basiliximab induction ( Figure 1 ). Belatacept therapy was discontinued at day 140 (d0: 10 mg/kg, d4: 15 mg/kg, d14-d56: 20 mg/kg biweekly, d56-d140: 20 mg/kg every 4 weeks). Tacrolimus levels were monitored weekly (8-12 ng/mL d0-d56, 5-8 ng/mL d57-d168, Figure S4 ). Expanded analysis of pretransplant immunophenotype included animals treated with CD28 domain antibody (36) or CD154 domain antibody (37) .
Mixed lymphocyte reaction and cell sorting
Peripheral blood mononuclear cells (PBMCs) were isolated from unmanipulated rhesus monkeys and fluorescently sorted based on CD28, CD45RA, and CCR7 expression. Responder cells were labeled with Cell Trace Violet (C34557; Invitrogen, Carlsbad, CA), and stimulators were labeled with carboxyfluorescein succinimidyl ester (Invitrogen, C34554). Cells were cultured in RPMI 1640 (Corning cellgro, Manassas, VA) supplemented with 10% fetal bovine serum AE 100 lg/mL belatacept (Bristol Myers-Squibb, Princeton, NJ).
Isolation of graft-infiltrating lymphocytes
To isolate graft-infiltrating lymphocytes, rejected allografts were mechanically disrupted, filtered through 70-lM cell strainers, washed in phosphate-buffered saline, and then filtered again through 40-lM cell strainers. Cell suspensions were separated by Ficoll-Paque density gradient centrifugation (GE Healthcare Life Sciences, Pittsburgh, PA) to isolate mononuclear cells. Mononuclear cells were washed twice and counted prior to antibody staining.
Antibodies and flow cytometric analysis
Flow cytometric analysis was performed up to three times pretransplant and serially posttransplant to characterize peripheral blood immune cell phenotypes. Total T cells and T cell subsets were quantified by complete blood cell count and flow cytometry. Fresh PBMCs were isolated by Ficoll density gradient centrifugation (BD Biosciences, Franklin Lakes, NJ). PBMCs were stained with the following mAbs: CD3 PacBlue, CD95 V450, CD3 Alexa 700, CD4 PerCP-Cy5.5, CD8 V500, CD28 PE-Cy7, CD25 PE-Cy7, IFNy PE-Cy7, CD28 APC, TNF APC, VLA-4 APC, CD11a PE, CD45RA FITC, CD40 FITC, CCR7 APC, and CD20 APC (all BD Biosciences). PBMCs (1. 
Statistics
Survival statistics were calculated using a log-rank test. T cell frequencies were compared using a parametric unpaired t-test. Decision tree analysis was performed with the programming language and statistical software R (v. 3.2.3), and utilized the "rpart" package. Data were analyzed using Prism 6 (GraphPad Software, La Jolla, CA). A two-tailed p-value of <0.05 was considered statistically significant.
Transcriptome analysis
RNA was prepared from biopsies of transplanted kidneys (at time of euthanizing), as well as from isolated graft-infiltrating cells. The quality of the total RNA from samples was monitored by the Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA) and RNA quantity was measured with NanoDrop (NanoDrop Technologies, Inc., Wilmington, DE) following the manufacturer's instructions. Two hundred nanograms of total RNA were amplified and labeled with 3 0 IVT Express Kit (Affymetrix, Santa Clara, CA). Labeled cRNA was hybridized on Affymetrix GeneChip Rhesus Macaque Genome Array (Cat. 900657, Affymetrix). Scanned images were subjected to visual inspection and a chip quality report was generated by Expression console (Affymetrix). The image data were processed using the Rhesus Macaque Array to determine the specific hybridizing signal for each gene. All chip data were loaded into BMS database (Bristol Myers-Squibb) for further analysis. Gene expression data were also analyzed utilizing DAVID Bioinformatics Database as described (38, 39) .
Results
Transplant recipients segregated based on response to belatacept therapy In order to investigate the mechanisms of rejection during belatacept treatment, 24 rhesus macaques were randomized to receive either belatacept-or tacrolimusbased immunosuppression following life-sustaining kidney transplant ( Figure 1 ). Animals continued to receive immunosuppressive therapy until day 140, at which time therapy was discontinued. We observed two distinct populations within each treatment group: belatacept-"resistant" animals that experienced rejection and graft failure during treatment, and belatacept-"susceptible" animals that maintained excellent graft function during administration of therapy ( Figure 2A ). Tacrolimus therapy similarly gave rise to resistant (n = 2) and susceptible (n = 6) animals ( Figure 2B ). Once all treatments were stopped, the remaining "susceptible" animals eventually succumbed to immune-mediated graft destruction in the absence of immunosuppression.
IL-2Ra blockade is utilized clinically as induction therapy and has demonstrated efficacy in combination with (5,40). There has been some concern that the addition of an antibody targeting CD25 may impact beneficial cell populations such as regulatory T cells and may negatively impact outcomes, particularly with newer strategies such as costimulatory blockade (41) . The addition of basiliximab to a subset of the belatacept-treated animals (n = 8) did not have a significant impact on the rate of rejection (rejectors on therapy n = 3/group) when compared to belatacept-treated animals that did not receive basiliximab induction (n = 3/group). Similarly there was no significant difference in survival between belatacept (mean survival time [MST] = 167 days), belatacept with basiliximab induction (MST = 189.5 days), or tacrolimus (MST = 183 days)-based immunosuppression ( Figure S1 ). All animals demonstrated excellent renal function as measured by serum creatinine until just prior to allograft rejection, defined as two consecutive serum creatinine values >5 ( Figure S1 ).
Elevated frequency of CD28
+ CD8 + T EMRA is associated with costimulation-resistant rejection An important question in the field of transplantation is the role of pretransplant immune memory status in transplant recipients, particularly in the context of costimulatory blockade-based immunosuppression. We and others have demonstrated elevated pre-existing immune memory, and more broadly, increasing prior pathogen exposure constitutes a potent barrier to transplant tolerance in murine and NHP models (42) (43) (44) . Other groups have found unique regulatory memory subsets in alternative models of transplantation (45) . To assess whether pretransplant memory immune phenotype could predict whether animals would respond to belatacept-based immunosuppression, we examined peripheral blood samples from all recipients prior to kidney transplantation using multiparameter flow cytometry. We then examined the association of the frequency of memory cell subsets and rejection. We found that belatacept-resistant animals, which rejected while on therapy, had higher baseline frequencies of CD28 + CD95 + CD8 + T cells prior to transplantation, compared to nonrejectors ( Figure 3C , p = 0.0402). A similar trend was not observed in the tacrolimus-treated animals ( Figure 3D T cells when phenotyping subsets in primates (21, 22, 25) . For a more granular analysis of the heterogeneous and functionally distinct memory and effector populations within CD3 + T cell compartment, we included additional conventional memory markers CD45RA and CCR7 (19, (25) (26) (27) . Utilizing a gating strategy involving these four memory markers ( Figure S6 ) revealed that belatacept-resistant rejection was highly associated with elevated pretransplant frequencies of CD28 + CD95 + CD45RA + CCR7 À CD8 T cells, so-called CD28 + CD8 + T EMRA ( Figure 4C and D, p < 0.0001). The pretransplant frequencies of CD28 + CD8
+ T EMRA were significantly elevated in belataceptresistant animals irrespective of whether they received basiliximab induction ( Figure S2C-F) . In contrast, tacrolimus-resistant animals did not exhibit similarly elevated pretransplant frequencies of CD28 + CD8 + T EMRA (Figure 4A and B, p = 0.2060). Belatacept-and tacrolimus-based immunosuppression gave rise to two distinct study populations: those animals that were "susceptible" to therapy (gray lines) and those that were "resistant" to treatment (black lines). Resistant animals experienced rejection and graft loss while treatment was ongoing (between day 0 and day 140). Susceptible animals experienced prolonged allograft survival for the entire duration of the therapy and only experienced rejection after withdrawal of therapy (after day 140). (A) Survival with belatacept therapy (n = 6 "resistant" animals and n = 10 "susceptible" animals). (B) Survival with tacrolimus treatment (n = 2 "resistant" animals and n = 6 "susceptible" animals).
In order to assess the generalizability of this biomarker to predict costimulation blockade-resistant rejection beyond belatacept treatment, we examined additional animals that had been treated with various costimulation blockade reagents that target either the CD28-CD80/86 or CD40-CD154 pathways. Similar to the belatacepttreated animals, we saw a clear distinction between "susceptible" and "resistant" animals using the pretransplant level of CD28 + CD8 + T effector memory CD45RA+cells (T EMRA ) ( Figure 4E and F, n = 37, p < 0.0001). We next performed a decision tree analysis on this same larger cohort utilizing all CD4 and CD8 T cell subsets, including memory subsets such as CD4+ and CD8+, effector memory T cells (T EM ) or T EMRA , accounting for CD28 expression. We found that a frequency of >3%
+ T cells provided the strongest predictor of costimulation blockade-resistant rejection in our model with an 87.5% sensitivity and 95.2% specificity ( Figure 4G ). For this model, the positive predictive value was 93.3% and the negative predictive value was 90.1% ( Figure 4G ). Tacrolimus-treated animals did not similarly segregate based on baseline frequencies of memory T cell subsets ( Figure 4A and B) , and thus we limited our decision tree analysis to the belatacept-treated cohort. À CD8 + T cell (CD8 + T EMRA ) compartment precipitously declined in the peripheral blood in belatacept-"resistant" animals ( Figure 5A and B) . The rapid decline of the CD28 + fraction of CD8 + T EMRA was observed in both belatacept-resistant animals irrespective of basiliximab induction ( Figure S3 ). When we examined the frequency of CD28 + cells within the CD8 + T EMRA subset 7 days prior to rejection, we found a significant decrease compared to baseline values (À19.24%, p = 0.0029, Figure 5C ).
CD28
In an effort to measure the proliferative capacity and effector function of alloreactive NHP T cell subsets, we sorted PBMCs from rhesus macaques into CD28 + and CD28 À T EMRA and performed a standard mixed lymphocyte reaction using allogeneic stimulators. We found that CD28 + CD8 + T EMRA had superior proliferative capacity compared to CD28 À
CD8
+ T EMRA cells (77.5% relative 
CD28
+ CD8 + T EMRA Promote Belatacept Rejection reduction in proliferative capacity, Figure 6A, 
Increased adhesion molecule expression is temporally associated with rejection
Mounting evidence has demonstrated a critical role for adhesion molecules such as CD49d (VLA-4) and CD11a (LFA-1) in mediating costimulation-independent allograft rejection (47-50). Analysis of adhesion marker expression on T cell subsets prior to transplantation revealed no significant difference in the frequency or intensity of VLA-4 or LFA-1 expression on CD8 + or CD4 + T cells between belatacept-"resistant" or -"susceptible" animals. After transplantation, however, circulating CD8 + and CD4 + T cells increased expression of VLA-4 and CD11a early in those animals resistant to belatacept therapy, particularly in the weeks preceding allograft rejection ( Figure 7A and B). Graft-infiltrating cells analyzed at the time of rejection in all treatment groups expressed uniformly high levels of VLA-4 and CD11a compared to baseline peripheral blood samples ( Figure 7C and D) . Taken together, these data suggest that CD28 + T EMRA may drive a costimulation-independent response where donor reactive cells rapidly expand and acquire effector function and then lose CD28 expression while upregulating adhesion molecules such as LFA-1 and VLA-4, allowing for access to the donor compartment. At the time of rejection, graft infiltrate of all animals demonstrated uniformly elevated levels of VLA-4 and CD11a expression, suggesting that expression of these molecules is part of "final common pathway" of allograft infiltration regardless of treatment.
Belatacept-resistant graft infiltrate is characterized by CD28
À CD8 + T EMRA As described above, treatment with belatacept gave rise to two distinct groups: those animals that rejected on therapy (<140 days): "resistant" and those that enjoyed À (CD28 + T EMRA ) as a frequency of total CD8 + T cells in pretransplant peripheral blood samples discriminates belatacept-resistant animals (black squares) from those susceptible to treatment (gray circles) with (D) corresponding survival curve (p < 0.0001). (E) In an expanded cohort of animals treated with costimulatory blockade reagents (either CD28 directed or CD154 directed blockade) we observed a similar pretransplant immunophenotype between resistant (black squares) and susceptible animals (gray circles), (F) corresponding aggregate survival curve. (G) Decision tree analysis determined that a cut-off value of 3.065% CD28 + CD8 + T EMRA segregated animals that would go on to experience costimulation-resistant rejection from those animals susceptible to costimulation blockade therapy (87.5% sensitivity, 95.23% specificity, 93.33% PPV and 90.09% NPV). PPV, positive predictive value; NPV, negative predictive value.
CD28
+ CD8 + T EMRA Promote Belatacept Rejection excellent graft function with minimal graft infiltrate on biopsy until therapy was withdrawn, at which time rejection ensued: "susceptible." In other words, "resistant" animals rejected on belatacept treatment while "susceptible" animals did not reject until therapy had been discontinued. We were interested to see whether the character of the rejection response differed between these two groups. Accordingly, we more closely examined the rejection response between belatacept-"resistant" and -"susceptible" groups at the time of graft failure. In general, allograft infiltrate was principally CD8 + T cells (60-70%), with a smaller CD4 + component (20-30%), in both groups (data not shown). These frequencies in graft infiltrate were reciprocal to the frequencies found in the peripheral blood where CD4 + T cells typically outnumbered CD8 + T cells 3 to 1. Belatacept-"resistant" animals exhibited a significant increase in CD8 + T EMRA graft-infiltrating cells extracted from rejected kidneys, whereas belatacept-susceptible animals exhibited a larger frequency of less fully differentiated CD8 + T EM , even though no difference in the frequency of these subsets existed in the peripheral blood before transplant ( Figure 8A and B) . Further analysis including CD28 expression status revealed a significant increased CD28 À
CD8
+ T EMRA in graft-infiltrating cells in resistant animals ( Figure 8E ), whereas susceptible animals exhibited a higher frequency of CD28 + CD8 + T EM ( Figure 8F ). These differences were not observed in tacrolimus-treated animals (Figure 8C and D, G-H) . In summary, when examining the character of the infiltrate at the time of rejection in "resistant" animals, the predominant cell subset was CD28 À CD8 + T EMRA compared to CD28 + CD8 + T EM in "susceptible" animals, suggesting that a more terminally differentiated subset was responsible for rejection in belatacept-"resistant" animals (representative flow plot, Figure 8I ).
Graft-infiltrating cells in belatacept-"resistant" rejection exhibit a transcriptional signature consistent with exhaustion
In an effort to further characterize the graft infiltrate in belatacept-resistant animals, we analyzed the gene-expression profile of graft tissue from belatacept-"resistant" versus -"susceptible" animals at the time of rejection. We identified unique modules of coordinated gene expression that were significantly divergent between the two groups. Unique chemokine and cytokines, increased trafficking and adhesion molecules, and increased expression of CD8 + T cell memory and exhaustion genes were associated with belatacept resistance (Figure 9A-C) . Pro-inflammatory chemokines and cytokines such as CXCL12, IL-6, and IL-15 were coordinately upregulated in belatacept-resistant animals compared to those that were susceptible to therapy ( Figure 9A ). Cytokine and chemokine receptors IL-17RA, IL12RB2, and CCR6 were also upregulated in belataceptresistant rejection, while CD25 (IL2RA), critical for regulatory T cell function, was downregulated. Genes associated with adhesion and trafficking such as ITGA4 and ITGB2 were upregulated in belatacept resistance ( Figure 9B ). Belatacept-resistant animals demonstrated significant upregulation of a number of coinhibitory receptors and memory transcription factors characteristic of and critical for terminally differentiated CD8 + T cells, such as several of the killer cell lectin-like receptors, EOMES, TBX21, BTLA, CTLA-4, and FAS ( Figure 9C ). Consistent with the flow cytometric analyses, these gene expression data suggest that the infiltrate associated with belatacept resistance is of a more fully differentiated T cell phenotype.
Discussion
Current immunosuppressive strategies most commonly employ a CNI, such as tacrolimus or cyclosporine, as the primary agent to prevent rejection following organ transplant. While these reagents provide for excellent initial 
CD28
+ CD8 + T EMRA Promote Belatacept Rejection Figure 8 : Belatacept resistance is marked by terminally differentiated T cells in the graft infiltrate. CD3 + CD8 + T cells extracted from rejected allografts were characterized by memory phenotype. (A) Belatacept-resistant animals (black squares) demonstrate a unique, increased frequency of CD8 T EMRA infiltrate within the graft compared to belatacept-susceptible animals (gray circles, p = 0.009). (B) Belatacept-susceptible animals (gray circles) that mount a rejection response in the absence of belatacept demonstrate a less differentiated CD8 + T EM infiltrate compared to belatacept-resistant animals (black squares, p = 0.0014). We next investigated the CD28 expression pattern on memory subsets. (E) Belatacept-resistant animals (black squares) demonstrated increased CD28 À
CD8
+ T EMRA compared to belatacept-susceptible animals (gray circles, p = 0.0166). (F) In contrast, belatacept-susceptible animals (gray circles) had increased levels of less fully differentiated CD28 + CD8 + T EM compared to belatacept-resistant animals (black squares, p = 0.0245). (I) Example plots of graft-infiltrating CD8 T cells in belatacept-resistant rejection and belatacept-susceptible animals that rejected after the withdrawal of therapy with the predominating phenotype distinctive of belatacept resistance (CD28 À
+ CD45RA + T EMRA , lower right quadrant) vs. belatacept susceptibility (CD28 + CD8 + CD45RA À T EM , upper left quadrant). These differences were not observed in tacrolimus-treated animals (C and D, G and H). T EM , effector memory T cells; T EMRA , T effector memory CD45RA+ cells.
outcomes, including 1-year patient and graft survival, long-term outcomes remain less than desirable (1,2,4) . There has been a concerted effort to develop new strategies to avoid unwanted side effects and improve late outcomes. While belatacept has established the promise of costimulation blockade to improve long-term outcomes, widespread adoption of this therapy has been limited by, among other things, increased rates of rejection and a perceived lack of efficacy. In an effort to better understand the underlying mechanisms leading to the resistance of costimulation blockade therapy, we designed a study in a preclinical model of NHP kidney transplantation Figure 9 : Distinct intragraft transcriptome modules define belatacept-resistant rejection. Transcriptome arrays from tissue acquired at the time of rejection revealed unique pathways augmented in belatacept resistance compared to belatacept susceptibility, as defined by KEGG and/or Biocarta pathway analysis. Analysis was restricted to differential gene expression between on-therapy rejection (belatacept resistant) compared to off-therapy rejection (belatacept susceptible). Genes involved in (A) cytokine and chemokine systems, (B) adhesion and migration, and (C) exhaustion and memory were upregulated in belatacept-resistant rejection. For example, CXCL12 was expressed 2.83-fold higher in belatacept-resistant graft tissue compared to belatacept-susceptible graft tissue, at the time of rejection. comparing animals treated with tacrolimus and belatacept. We identified a pretransplant immunophenotype in the peripheral blood of elevated CD28 + CD8 + T EMRA cells that discriminates animals that go on to experience costimulation blockade-resistant rejection from those that are susceptible to therapy. These CD28 + T EMRA retain proliferative capacity in addition to other effector functions, unlike their CD28
À counterparts. Furthermore, we show that these cells likely downregulate CD28 or give rise to a population of CD28 À effector/T EM , which constitute the major component of the infiltrate in rejected kidneys in resistant animals. Along with data presented in our companion study in human patients, we suggest that this relatively straightforward test could potentially be used as a pretransplant screen to determine eligibility for belatacept therapy (34) .
There are several differences between our findings in the NHP model and what was observed in patients. First, there tended to be a tighter link between increased frequencies of CD28 + CD4
+ T EM/EMRA and a higher likelihood of rejection in human patients, whereas in our NHP study we found the pretransplant level of CD28 + CD8
+ T EMRA was more highly associated with costimulation-independent rejection. There are many differences between NHPs and humans, including age and immune experience that are likely contributors. Animals used in our studies are captivebred juveniles and may not have the same degree of immune exposures as older adult humans. Moreover, human transplant recipients, unlike the healthy primates, all have end-stage renal disease with its accompanying uremia and almost universal dialysis requirement, factors that can contribute to an inflammatory environment causing immune dysregulation, perhaps differentially affecting some cell subsets more than others.
We initially hypothesized that higher baseline levels of CD28 À memory T cells may be predictive of costimulation-independent rejection (15, 16, 48) . On a cursory level, this subset would appear to be poised to avoid the effects of belatacept, given the lack of the receptor for the targeted pathway. However, a more comprehensive view of this subset suggests that the lack of CD28 expression accompanies cells that have a more differentiated phenotype, usually following antigen exposure and activation (51) . These cells often demonstrate diminished proliferative capacity despite their immediate effector capabilities. While not completely clear, we suggest from our studies that CD28 À cells, although potentially potent effector cells, may not possess the capacity to sustain a response that would lead to rejection of the transplanted organ. Rather we believe that CD28 expression on T EM / T EMRA designates a cells subset that has a combination of proliferative reserve and cytolytic capacity. In fact, we showed that CD28 + CD8 + T EMRA proliferate readily in mixed lymphocyte reaction despite belatacept treatment, and that CD28 À CD8 + T EMRA lack proliferative potential. Interestingly, we observed that while CD8 + T EMRA cell frequencies remain stable during transplantation, there is a rapid loss of the CD28 + fraction. We further demonstrate CD28 À CD8 + T EMRA uniquely compose a predominate fraction of the allograft infiltrate at the time of rejection in belatacept-resistant rejection.
The stability of this phenotype is unknown (i.e. higher frequency of CD28 + CD8 + T EMRA ). Multiple factors may drive increased CD28 expression on T EMRA and T EM . Viral-specific memory T cells from prior pathogen exposure exhibit distinct memory phenotypes based on CD45RA, CCR7, CD28, and CD95 expression. T cell memory phenotype is subject to change based on chronicity of antigen exposure, acuity of infection, or heterologous challenge (19, 52) . Consistent with our work, previous studies have identified a highly proliferative and potently cytolytic CD28 + CD8 + T EMRA cell subset in patients vaccinated for yellow fever (53) . Additional investigation into the factors contributing to rejection associated with a higher level of CD28 + T EMRA is required. Work by our group and others suggests that differential expression of coinhibitory molecules such as CTLA-4 may be responsible for preferential activation of some T cell subsets when belatacept is used. Further studies are needed to examine the longitudinal stability of this phenotype and whether interventions such as cytokine deprivation via antibody administration or periods of lower overall inflammation/immune stimulation may allow for a decrease in this subset. More importantly, if the level of CD28 + T EMRA changes over time and drops below the 3% level, are animals that were once "resistant" to costimulation blockade now "susceptible" to therapy? These important questions require additional investigation.
Transcriptomic analysis of the allograft infiltrate suggests that an augmented pro-inflammatory milieu leads to a more fully differentiated T cell infiltrate consistent with the phenotype obtained from flow cytometry. Taken together, these data suggest that one mechanism of belatacept resistance is mediated by CD28-bearing memory cells that leverage a proliferative advantage in order to sustain alloreactivity, while further differentiating and increasingly relying on alternative signals (i.e. killer immunoglobulin-like receptors, c-chain cytokines, inflammatory chemokines, adhesion molecules) to prosecute costimulation-independent rejection. Studies aimed at high-resolution spatial and temporal tracking of memory T cells will increase our understanding of the ontology, kinetics, and plasticity of T cell memory subsets. These studies may inform how and when to leverage dynamic T cell signaling sensitivities to promote transplant tolerance. 
Disclosure
Figure S1: Graft function and survival. Animals were assessed weekly for renal function utilizing serum creatinine. Depressed renal function pursuant to allograft rejection was determined by two consecutive Cr > 5. Resistant animals (black lines) and susceptible animals (gray lines). Weekly serum creatinine and corresponding survival curves of belatacept-treated animals (A and B), belatacept-treated animals that received basiliximab induction (C and D), and tacrolimus-treated animals (E and F). Survival analysis revealed no statistically significant differences between treatment groups, belatacept vs. basiliximab+belatacept (B, P 1 = 0.1122) or belatacept vs. basiliximab+tacrolimus (B, P 2 = 0.1175), or basiliximab+belatacept versus basiliximab+tacrolimus (p = 0.6678). Belatacept and basiliximab+belatacept-treated animals demonstrated an identical rate of therapeutic resistance (n = 3/grp). Figure S4: Mean Prograf (tacrolimus) levels. Tacrolimustreated animals were monitored weekly for Prograf levels, and doses were adjusted in order to maintain blood levels from 8 to 12 ng/mL up to day 56, and 5 to 8 ng/mL until day 140. Figure S5 : CMV reactivation. Animals in all treatment groups (A) belatacept, (B) belatacept + basiliximab, (C) tacrolimus + basiliximab experienced infrequent (n = 1/group) and equivalent rates of CMV reactivation, defined as >10 000 copies of viral DNA/lL of blood, as measured by quantitative PCR. Figure S6 : Gating strategy for pretransplant immunophenotyping. Gating strategy involved gating first on lymphocytes, then CD3 + cells, then CD8 + (vs. CD4 + ). Gates were then set on CD28 + CD95 + cells as pictured. CD28 + CD95 + cells were then further analyzed by CD45RA and CCR7, as pictured. Sample plots show pretransplant flow cytometry from one therapy-resistant animal (top) and therapy-susceptible animal (bottom).
